Cyclacel Pharmaceuticals, Inc. announced that effective November 9, 2020, the Board of Directors appointed Karin L. Walker to serve as a Class 1 Director until the 2022 annual meeting of the Company’s stockholders. There are no arrangements or understandings between Ms. Walker and any other person pursuant to which Ms. Walker was appointed as a director. Ms. Walker has over 30 years of extensive finance experience in biopharmaceuticals, including in public biotechnology companies and technology companies. Ms. Walker currently serves as the Chief Accounting Officer of Prothena Corporation plc. Prior to joining Prothena, she was Vice President, Finance and Chief Accounting Officer of Affymax, Inc.